Adjuvant Therapy for Lung Cancer in the Elderly

摘要: Adjuvant chemotherapy improves 5-year survival after resection of nonsmall cell lung cancer by approximately 10%. therapy is most appropriate for patients with node-positive disease (N1 or N2) a primary tumor greater than 4 cm. The best available data suggests that the elderly, certainly those between ages 65 and 75, accrue benefit similar to younger patients, despite inferior dose delivery. However, are sparse above age 75. Although platinum doublets have been accepted as standard care, no consensus has emerged optimal agent be partnered drug. For good kidney function normal hearing, cisplatin remains drug choice. carboplatin must often substituted. Clinical trials evaluating new targeted agents molecular markers ongoing should shed further light on approaches elderly.